Dennis J. Murphy, PhD, DABT Director - Safety Pharmacology US

Slides:



Advertisements
Similar presentations
Office of New Animal Drug Evaluation Laura L. Hungerford, DVM, MPH, PhD Senior Advisor, Science and Policy, ONADE Professor, University of Maryland School.
Advertisements

Research Study Designs
Page 1 1 FDA Advisory Committee Meeting “Safety Considerations in the Development of Ultrasound Contrast Agents” June 24, 2008 Nonclinical Development.
Regulatory Toxicology James Swenberg, D.V.M., Ph.D.
Quantitative Skills 4: The Chi-Square Test
CHAPTER 8 EXPERIMENTAL DESIGN.
Effectiveness Evaluation for Therapeutic Drugs for Non-Food Animals
Food and Drug Administration Preclinical safety data for “first in human” (FIH) clinical trials in healthy volunteer subjects Oncology Drug Advisory Committee.
CDER IND/NDA Reviews Guidance, The Common Technical Document and Good Review Practice John K. Leighton, Ph.D., DABT CDER/FDA.
Venkata Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.
Sedation.
Designs for Clinical Trials. Chapter 5 Reading Instructions 5.1: Introduction 5.2: Parallel Group Designs (read) 5.3: Cluster Randomized Designs (less.
Exploratory IND Studies
Adding Safety Pharm Endopoints To General Tox Studies - II Michael J Engwall, DVM, PhD Principal Scientist Safety and Exploratory Pharmacology Toxicology.
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
Integrating functional CNS observations into toxicology studies: Preliminary Results from An Industry Survey Simon Authier, DVM, MBA, PhD Director - Safety.
Respiratory Safety Pharmacology Endpoints in Toxicology Simon Authier, DVM, MBA, PhD Director - Safety Pharmacology and Veterinary Science CIToxLAB North.
Biomedical Research.
AN INTRODUCTION TO CLINICAL PHARMACOLOGY. BEFORE STARTING DRUG THERAPY, DOCTORS CONSIDER  Whether intervention needed ?  Objective of treatment ? 
1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.
In rodent studies, microsampling provides an opportunity to sample main study animals for toxicokinetic (TK) assessment rather than using satellite animals.
Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.
Safety Pharmacology Society Webinar Series: Safety Pharmacology Endpoints: Integration into Toxicology Studies Integrating functional CNS observations.
Bioequivalence Dr Mohammad Issa Saleh.
Premarket Testing and Validation "The greatest lesson in life is to know that even fools are right sometimes" Sir Winston ChurchillWinston Churchill.
Consider Incorporating Respiratory Safety Pharmacology Measurements into Your Next Repeat Dose Toxicology Study September 14, 2012 Jeff Tepper, PhD, DABT.
A Literature Review to Investigate if Blood Compatibility Tests are a Necessary Procedure in the Pharmaceutical Industry to Predict Adverse Toxicology.
“Journey of a Drug” From Test Tube TO Prescribing Physician.
Penn CTSI Research Seminar Clinical Trials November 10, 2015 Vernon M. Chinchilli, PhD Distinguished Professor and Chair Department of Public Health Sciences.
Respiratory Inductive Plethysmography Data Analysis GUI Chad Dziak Thanh Vuong.
Physiological measures of welfare 1 Module 3 Learning objectives To understand the relationship between welfare and physiology To examine how the autonomic.
Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children: Cardiovascular.
Concussion Guidelines in the GAA
Clinical Decision Support Systems in the Perioperative Setting
for Human Pharmaceuticals Kyung-Chul Choi D.V.M., Ph.D.
Welcome Clinical Trials October 11, 2016 Vernon M. Chinchilli, PhD
DRUG DISCOVERY AND DEVELOPMENT
Chapter 4 Research Methods in Clinical Psychology
Pre-Investigational New Drug (pre-IND) Meeting with FDA
THE SELF SUSTAINING NON-PROFIT Golden Lessons From the Development and Corporate Sectors 14th Eastern Africa Resource Mobilization Workshop Paper.
Solid dosage forms Tablets
Cardiovascular Safety Assessment Before and During Exercise Stress in Normal and Heart Failure Dog Models Presenting Author: Craig Hassler Additional.
Statistical Core Didactic
Mechanical Ventilation
Regulatory Toxicology & Risk Assessment in Consulting
Regulatory Perspective
Do now! Task: Go through your exam papers, with a different coloured pen attempt to make the necessary corrections. Do not ask me! Use your book or someone.
Pesticides and the Wirtzs, Part III: Communication and Dosing
Conscious Sedation March, 2012.
Allergic Reaction Protocol Preparing & Administering Epinephrine IM
NSSGA Mineral Identification and Management Guide
What do I Need to Recertify?
Crucial Statistical Caveats for Percutaneous Valve Trials
Larry Tash Director of School Redesign, LAUSD February 8, 2008
ICES led Reviews of D3, D4, D6 & D11
Learning Styles Naviance.
Introduction to Clinical Pharmacology Chapter 16 Opioid Antagonists
Data collection and activity analysis
CTD Module 4: Non-Clinical Studies SPC Relevant Scientific information
Drug Delivery Systems Pharmaceutical technology Petra University.
acute, chronic, or acute on chronic.
Ayman Grada, MD, Joshua Mervis BS, Vincent Falanga, MD, FACP
Volume 24, Issue 7, Pages (March 2014)
WSES guidelines for diagnosis and management of acute appendicitis.
LEARNING AND PERFORMING WILDLIFE RESEARCH THROUGH THE MUSKRAT
Introduction to Clinical Pharmacology Chapter 16 Opioid Antagonists
INTENTIONAL HUMAN DOSING STUDIES (IHDS)
Sharon C. Murray, PhD JSM 29 July 2019
VICH GL 54, Studies to evaluate the safety of residues of veterinary drugs in human food: General approach to establish an Acute Reference Dose (ARfD)
Presentation transcript:

Advantages of Conducting a Stand-Alone Respiratory Safety Pharmacology Study Dennis J. Murphy, PhD, DABT Director - Safety Pharmacology US GlaxoSmithKline Pharmaceuticals

Advantages Ventilatory measurements in animal models can be highly variable due primarily to a sensitivity to environmental changes (stimuli) Stimuli include noise, odor, movement, handling, light, temperature As such, measurements require a highly controlled environment for accurate and repeatable measurements This can be achieved in a stand-alone study Very difficult to achieve in a typical toxicology study where many activities are constantly ongoing and high number of animals are involved Stand-alone studies allow the use of animals with a telemetry implant for measuring body temperature and pleural pressure (required to obtain a direct measure of airway resistance) Generally not acceptable in a toxicology study due to pathology complications and resource limitations

Advantages (continued) Stand-alone studies have greater flexibility in study design Can use either crossover designs (animals serve as their own control) or parallel design with n = 6-8 of single sex per dose group Can include recovery time for assessing reversibility or delayed effects (beyond 24 hrs post dose) A typical 2/4 week toxicology study can be limited to a parallel design with n=3/sex per dose group (non-rodent) (sufficient for statistical analysis?) and may not include a recovery period (rodent or non-rodent) Acute (day 1) measurements can be obtained with stand-alone studies Day 1 measurements are critical because of tachyphylaxis or tolerance/compensation that can develop on repeat dosing This can be difficult in toxicology studies because of TK analysis and enhanced clinical observations that need to be conducted on day1